What are the Historical Developments and Current Growth Metrics of the Biologics CDMO Market?
The biologics cdmo market has seen considerable growth due to a variety of factors.
• The market size of biologics cdmo has been expanding rapidly in recent times. It's projected to magnify from $21.3 billion in 2024 to $24.37 billion in 2025, boasting a compound annual growth rate (CAGR) of 14.4%.
The substantial growth during the historic phase is credited to increased development in biologics, cost-effectiveness as well as flexibility, focus on pivotal competencies, adherence to regulatory requirements, the assurance of quality and the globalization of pharmaceutical supply chains.
What is the Forecasted Market Size and CAGR for the Biologics CDMO Market?
The biologics cdmo market is expected to maintain its strong growth trajectory in upcoming years.
• Expectations are high for the biologics cdmo market, as it is predicted to experience a swift rise in growth in the forthcoming years. It is projected to reach a value of $42.33 billion by 2029, expanding at a compound annual growth rate (CAGR) of 14.8%.
Factors contributing to this growth within the forecast period include a growing demand for biologic therapies, the introduction of biosimilars and biobetters, increased investment in biomanufacturing facilities, a shift towards the outsourcing of complex procedures, focus on strengthening supply chain resiliency and risk reduction, regulatory unification, and expedited approval processes. During the forecast period, key market trends will include broadening capabilities to provide comprehensive solutions, adopting disposable technologies, incorporating continuous manufacturing processes, and the emergence of specialized CDMOs.
What Key Factors and Trends Are Driving The Growth Biologics CDMO Market?
The increase in demand for cellular and genetic treatments is anticipated to stimulate the expansion of the biologic CDMO market in the future. Cell and gene therapies are revolutionary medical interventions that employ living cells or genetic substances to tackle the root causes of diseases at the cellular or genetic level, offering potential remedies for conditions that are challenging to treat or incurable with conventional pharmaceuticals. The growing demand for cell and gene therapies is due to their capacity to provide groundbreaking treatments for diseases by tackling the root genetic or cellular causes. Biologic CDMOs are proficient in managing living cells, viral vectors, and genetic substances, ensuring the safe and effective manufacturing of cell and gene therapies while aiding biopharmaceutical firms in overcoming regulatory necessities and technical hurdles, thus easing the transition from research to clinical application. For example, in January 2023, The American Society of Gene & Cell Therapy (ASGCT), a primary professional membership body based in the US, reported that the gene, cell, and RNA therapy pipeline had expanded by 7% in 2022, totaling 3,726 therapies under development. Of these, 55% are gene therapies, 22% are non-genetically modified cell therapies, and 23% are RNA therapies. Hence, the rising demand for cell and genetic therapy is fuelling the expansion of the biologic CDMO market.
What Are The Market Segments In The Biologics CDMO Market?
The biologics cdmo market covered in this report is segmented –
1) By Cell Type: Mammalian, Non-Mammalian
2) By Product Type: Biologics, Biosimilars
Subsegments:
1) By Mammalian: Chinese Hamster Ovary (CHO) Cells, Human Embryonic Kidney (HEK) Cells, Other Mammalian Cells
2) By Non-Mammalian: Yeast Cells, Bacterial Cells, Insect Cells, Other Non-Mammalian Cells
Pre-Book The Biologics CDMO Global Market Report 2025 Report For Swift Delivery And Comprehensive Insights:
What Trends Are Shaping The Biologics CDMO Market?
In the biologics CDMO market, leading firms are focusing on the creation of state-of-the-art solutions, including novel cell lines, to augment their biopharmaceutical creation and manufacturing skills and efficacy. This advanced technology is being used to create therapeutic antibodies with improved strength, tackling obstacles in immunotherapy research and development. As an example, Lonza Group, a Swiss-based firm known for its expertise in the pharmaceutical and biotech fields, rolled out GS Effex cell lines in November 2023. These cell lines are engineered to create antibodies that are completely devoid of the sugar molecule fucose, without compromising on any other performance aspects. The increased potency addresses the challenges in immunotherapy R&D that require enhanced potency of antibody therapeutics. This cell line, which is stable, scalable, and productive, provides a solution for therapeutic development from the early stages of discovery through to commercial production.
Who Are the Key Players In The Biologics CDMO Market?
Major companies operating in the biologics CDMO market are:
• AbbVie Inc.
• Thermo Fisher Scientific Inc.
• Novartis AG
• Evonik Industries AG
• Sandoz International GmbH
• ICON PLC
• Grifols SA
• Lonza Group Ltd.
• Boehringer Ingelheim International GmbH
• Catalent Inc.
• JSR Corp.
• Parexel International Corporation
• WuXi Biologics (Cayman) Inc.
• Samsung Biologics Co. Ltd.
• Emergent BioSolutions Inc.
• Rentschler Biopharma SE
• FUJIFILM Diosynth Biotechnologies U.S.A. Inc.
• Binex Co. Ltd.
• Bora Pharmaceuticals Co. Ltd
• 3P Biopharmaceuticals s.l.u
• JRS Pharma LP
• J Rettenmaier and SOHNE GmbH and Co KG
• Kemwell Biopharma Pvt. Ltd.
• Cytovance Biologics
• AGC Biologics
• Shenzhen Hepalink Pharmaceutical Co. Ltd.
What Are The Regional Insights Into The Biologics CDMO Market?
North America was the largest region in the biologics CDMO market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the biologics CDMO market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
